CellCept, Myfortic Labeling Get PML Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling update for transplant drugs follows postmarketing reports of progressive multifocal leukoencephalopathy.
You may also be interested in...
Immunosuppressant Drug Labels Updated To Reflect Infection Risk
FDA requires the labels for a handful of immunosuppressants used in kidney transplantation to reflect risk of infection, including activation of latent viral infections.
Immunosuppressant Drug Labels Updated To Reflect Infection Risk
FDA requires the labels for a handful of immunosuppressants used in kidney transplantation to reflect risk of infection, including activation of latent viral infections.
FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
PML could be a hazard, too, agency says.